Insulin Resistance – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Insulin Resistance Market Outlook

Thelansis’s “Insulin Resistance Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Insulin Resistance treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Insulin Resistance Overview

Insulin resistance is when the body exhibits an insufficient biological response to normal insulin levels. In essence, it can affect various insulin-related functions in different bodily tissues. However, in clinical practice, insulin resistance is commonly understood as a state in which a given amount of insulin results in an inadequate glucose response. The origins of insulin resistance can be attributed to genetic and acquired factors. Genetic factors include mutations in insulin receptors, glucose transporters, and signaling proteins, although the precise causes of common forms remain largely unknown. Acquired factors encompass physical inactivity, dietary habits, medications, high blood sugar levels (known as glucose toxicity), elevated levels of free fatty acids, and the natural aging process. The underlying causes of insulin resistance can be classified based on whether their primary impact occurs before, at, or after the insulin receptor. Pre-receptor causes include abnormal insulin (due to mutations) and anti-insulin antibodies. Receptor-related causes include reduced receptors, failure to activate tyrosine kinase, diminished insulin binding, insulin receptor mutations, and antibodies that block insulin receptors. Post-receptor causes encompass defective signal transduction and, in theory, mutations in the GLUT4 gene, although these mutations are rare. Symptoms of insulin resistance encompass increased thirst, frequent urination, heightened appetite, blurred vision, headaches, vaginal and skin infections, and slow wound healing. Factors associated with a higher likelihood of developing insulin resistance include a strong family history of diabetes, gestational diabetes, and polycystic ovary syndrome. Impaired glucose metabolism, defined as fasting glucose levels between 110 and 125 mg per dL (6.1 and 7.1 mmol per L) or impaired glucose tolerance with a two-hour post–75-g glucose load level between 140 and 199 mg per dL (7.8 and 11.1 mmol per L), also contribute to this condition. Additionally, obesity, defined as a body mass index of 30 kg per m2 or higher, and an increased waist-to-hip ratio (1.0 in men and 0.8 in women) are associated with insulin resistance.

• Globally, the prevalence of insulin resistance among adults varies, ranging from 15.5% to 46.5%. The lowest prevalence is observed among underweight individuals (7.1%), while the highest rates are found among those who are obese (45%).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: